Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
Open access

Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan

Shih-Te Tu Chiao-Fan Chiu Chu-Kuang Chou Hai-Hua Chuang Shu-Wei Hu Wen-Ching Ko Chun-Ying Lee Wen-Yuan Lin Yen-Jen Sung Thing-Fong Tzeng Weu Wang Hsiang-Fan Wu Chun-Yan Yeung Bill Chen Chet Joe Sim Kuo-Chin Huang
Sep 2026 · Endocrinology, Diabetes & Metabolism · Vol 9 · 1 citation · 39 references
Medicine

Abstract

This prospective study (NCT06283641) was the first real‐world, multicentre, post‐marketing surveillance of GLP‐1 receptor agonist liraglutide as an adjunct for weight management in adults with obesity in Taiwan.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).

Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al. · 0 citations
Open access Sep 2026

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D).

M. P. A. Baldassarre, G. Di Dalmazi, Federica Carrieri et al. · 0 citations
Open access Oct 2026

Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity

This cohort study evaluates early treatment trends of oral semaglutide among adults eligible for obesity management medications following its approval for obesity.

Yu-Qing Lei, Hui-Lin Tang, Xin-Yao Jian et al. · 0 citations
Open access Oct 2026

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.

Jun-Sung Moon, K. Han, Dong-Lim Kim et al. · 0 citations
Open access Jul 2026

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset

Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction‐associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis.

Maria Mironova, K. Padmanabhan, David Schneider et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.